SURVYR

RPRX

Royalty Pharma plc
$64.82
−$0.46 (0.70%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-7%+14%+36%+57%+79%Oct 2025Oct 2026Apr 202652w high $64.3852w low $35.91
RPRXSPY
Wall St. Highest PT $70.00 (+8.0%) Wall St. Avg PT $65.38 (+0.9%)
$36$45$54$63$72POC $58Hi $70Avg $65
Underwater Drawdown %Max DD -12.1%Current -0.7%
0.0%-12.1%
Relative Strength vs SPY+63.4% vs SPYOutperforming
+75%0%-75%
1W
+$2.67 (4.30%)
1M
+$6.45 (11.05%)
3M
+$5.88 (9.97%)
6M
+$15.75 (32.08%)
YTD
+$26.70 (70.06%)
1Y
+$29.10 (81.48%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
8 analysts · mean score 1.50
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$64.82
Average target$65.38
+$0.56 (+0.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$61.00
Median$65.38
High$70.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-07 · Morgan Stanley reiterated Overweight on RPRX
Reiterated
2026-09-08 · TD Cowen reiterated Buy on RPRX
Reiterated
2026-08-07 · JP Morgan reiterated Overweight on RPRX
Reiterated
2026-07-13 · TD Cowen reiterated Buy on RPRX
Reiterated
2026-05-07 · Citigroup reiterated Buy on RPRX
Reiterated
2026-05-07 · JP Morgan reiterated Overweight on RPRX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$36.1B
P/E (last 12 months)33.2
P/E (next 12 months, estimated)10.8
52-week range$35.91 – $64.38
Revenue growth (latest quarter vs a year ago)+16.5%
Dividend yield1.51%
Analyst consensusStrong Buy (8)
Average analyst price target$65.38 (+1%)

What they do

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for RPRX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 24 of 589 · 12-month momentum 77.6%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

RPRX earningsNext report in 6 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Before the open
EPS consensus$1.18 range $1.15–$1.22
Revenue consensus$884.8M 4 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026$1.32est $1.27+3.9%Above estimates
May 6, 2026$1.30est $1.18+9.4%Above estimates
Feb 11, 2026$1.47est $1.33+9.9%Above estimates
Nov 5, 2025$1.17est $1.04+12.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 11:27:54 ET
24-1125-0225-0525-0825-1126-0226-0526-080.001.47
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$674.1M+16.5%
2026-03-31$630.6M–
2025-12-31$622.0M–
2025-09-30$609.3M–
2025-06-30$578.7M–

Recent dividends

2026-08-14: $0.235 · 2026-05-15: $0.235 · 2026-02-20: $0.235 · 2025-11-14: $0.220 · 2025-08-15: $0.220 · 2025-05-16: $0.220 · 2025-02-21: $0.220 · 2024-11-15: $0.210

News & catalysts

More news
Royalty Pharma declares fourth quarter 2026 dividend
GlobeNewswire · Oct 16
Royalty Pharma (RPRX) Offers Attractive Risk-Reward Profiles at Reasonable Multiples
Insider Monkey · Oct 12
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
GlobeNewswire · Oct 09
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
Zacks · Oct 08
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Motley Fool · Oct 01
Rating changes
Reiterated
2026-10-07 · Morgan Stanley reiterated Overweight on RPRX
Reiterated
2026-09-08 · TD Cowen reiterated Buy on RPRX
Reiterated
2026-08-07 · JP Morgan reiterated Overweight on RPRX
Reiterated
2026-07-13 · TD Cowen reiterated Buy on RPRX
Reiterated
2026-05-07 · Citigroup reiterated Buy on RPRX
Reiterated
2026-05-07 · JP Morgan reiterated Overweight on RPRX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Urist Marshall
EVP, Research & Investments · 2026-10-05
Sell
$235.6K
Urist Marshall
EVP, Research & Investments · 2026-09-28
Sell
$238.8K
Hite Christopher
EVP & Chairman, Partnering · 2026-09-22
Sell
$231.4K
Hite Christopher
EVP & Chairman, Partnering · 2026-09-22
Sell
$5.6M
Hite Christopher
EVP & Chairman, Partnering · 2026-08-18
Sell
$6.0M
Coyne Terrance P.
EVP & CFO · 2026-08-13
Sell
$104.8K
Coyne Terrance P.
EVP & CFO · 2026-08-13
Sell
$540.8K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 11:27:54 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026